Therapeutic drug monitoring of antidepressants - Clinical aspects

Journal of Neural Transmission, Supplementa

Volumn , Issue 72, 2007, Pages 261-267

  Laux, G ^a   Baumann, P ^b   Hiemke, C ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

antidepressants; Drug monitoring; pharmacotherapy; pharmacovigilance

Indexed keywords

ANTIDEPRESSANT AGENT;

BLOOD; DEPRESSION; DOSE RESPONSE; DRUG INTERACTION; DRUG MONITORING; HEALTH CARE QUALITY; HUMAN; METHODOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; TREATMENT OUTCOME;

EID: 38449108963     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-73574-9_32     Document Type: Review

References (30)

1. Alexanderson BH, Evans DA, Sjoqvist S (1969) Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 686:764-768
2. Asberg M, Cronholm B, Sjöqvist F, Tuck D (1971) Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 3:331-334
3. Balant-Gorgia EA, Balant LP (1995) Therapeutic drug monitoring - Relevance during the drug treatment of psychiatric disorders. CNS Drugs 4:432-453
4. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5-43
5. Baumann P (1996) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31:444-469
6. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004) The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37:243-265
7. Baumann P, Ulrich S, Eckermann G, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G, Hiemke C (2005) The AGNP-TDM expert group consensus guidelines: focus on therapeutic drug monitoring of antidepressants. Dialogues Clin Neurosci 7:231-247
8. Bertilsson L, Mellström B, Sjöqvist F, Mårtensson B, Åsberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 339:560-561
9. Burke MJ, Preskorn SH (1999) Therapeutic drug monitoring of antidepressants. Cost implications and relevance to clinical practice. Clin Pharmacokinet 37:147-165
10. Fava M, Davidson KG (1996) Definition and epidemiology of treatmentresistant depression. Psychiat Clin N Am 19:179-200
11. Glassmann AH, Schildkraut JJ, Orsulak PJ, Cooper TB (1985) Tricyclic antidepressants, blood level measurements and clinical outcome: an APA task force report. Am J Psychiatry 142:155-162
12. Goodnick PJ (1994) Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 27:307-330
13. Hiemke C, Laux G (2002) Therapeutisches Drug-Monitoring von Antidepressiva. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka. Ein Therapie-Handbuch. Bd. 3, Antidepressiva. 2. Aufl., Springer, Wien New York, pp 911-922
14. Hiemke C, Baumann P, Laux G, Kuss HJ (2005) Therapeutisches Drug-Monitorung in der Psychiatrie. Konsensus-Leitlinie der AGNP. Psychopharmakotherap 12:166-182
15. Johnson D (1996) Noncompliance with antidepressant therapy - an underestimated problem. Intern Med 11:14-17
16. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots J (2001) CYP2D6 and CYP2C19 genotype-based dose recommendation-specific dosages. Acta Psychiatr Scand 104:73-192
17. Laux G, Riederer P (eds) (1992) Plasmaspiegelbestimmung von Psychopharmaka: Therapeutisches Drug - Monitoring. Versuch einer ersten Standortbestimmung. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 7-128
18. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J (2000) Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 101:354-359
19. Mann K, Hiemke C, Schmidt LG, Bates DW (2006) Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 28:83-88
20. Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C (2003) Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions. Pharmacopsychiatry 36:98-104
21. Orsulak PJ (1989) Therapeutic monitoring of antidepressant drugs - Guidelines updated. Ther Drug Monit 11:497-507
22. Perry PJ, Zeilmann C, Arndt S (1994) Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14:230-240
23. Preskorn SH, Fast GA (1991) Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 52 [Suppl 6]: 23-33
24. Rasmussen BB, Brosen K (2000) Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22:143-154
25. Regenthal R, Krueger M, Koeppel C, Preiss R (1999) Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 15:529-544
26. Riederer P, Laux G (1992) Therapeutic drug monitoring of psychotropics: report of a consensus conference. Pharmacopsychiatry 25:271-272
27. Simmons SA, Perry PJ, Rickert ED, Browne JL (1985) Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients. J Affect Disord 8:47-53
28. Ulrich S, Läuter J (2002) Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet 41:853-876
29. Vuille F, Amey M, Baumann P (1991) Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility. Pharmacopsychiatry 24:190-195
30. Zernig G, Lechner T, Kramer-Reinstadler K, Hinterhuber H, Hiemke C, Saria A (2004) What the clinician still has to be reminded of. Ther Drug Monit 26:582